Melanoma trials recruiting in Maryland

All Melanoma trials nationally

Cities in Maryland

Recruiting trials in Maryland

• A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
  NCT02621021 · Phase: Phase 2 · Ages: 18 Years to 72 Years · Sex: All (male and female) · Maryland: Bethesda
• A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
  NCT06246916 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Columbia
• A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
  NCT07492680 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore
• A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
  NCT06172478 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore
• A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
  NCT06066138 · Phase: Phase 1 · Ages: 18 Years to 120 Years · Sex: All (male and female) · Maryland: Bethesda
• A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
  NCT05592626 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Bethesda
• Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
  NCT02830724 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 72 Years · Sex: All (male and female) · Maryland: Bethesda
• Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
  NCT06418204 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore, Elkton, Glen Burnie, Towson
• Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
  NCT00040352 · Phase: Not specified · Ages: 4 Weeks to 99 Years · Sex: All (male and female) · Maryland: Bethesda
• Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
  NCT05334069 · Phase: Not specified · Ages: 40 Years to 75 Years · Sex: All (male and female) · Maryland: Baltimore, Bethesda, Clinton, Easton
• DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
  NCT06953089 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Bethesda
• Dabrafenib and/or Trametinib Rollover Study
  NCT03340506 · Phase: Phase 4 · Ages: 18 Years to 100 Years · Sex: All (male and female) · Maryland: Bethesda
• Evaluation for NCI Surgery Branch Clinical Research Protocols
  NCT00001823 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Bethesda
• Excision of Lymph Node Trial (EXCILYNT) (Mel69)
  NCT05839912 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore
• Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
  NCT05896839 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore
• Integrated Cancer Repository for Cancer Research
  NCT02012699 · Phase: Not specified · Ages: 19 Years to 110 Years · Sex: All (male and female) · Maryland: Randallstown, Westminster
• Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
  NCT03860883 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore
• Neoadjuvant Darovasertib in Primary Uveal Melanoma
  NCT07015190 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore
• Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
  NCT05155033 · Phase: Phase 2 · Ages: 18 Years to 120 Years · Sex: All (male and female) · Maryland: Bethesda
• Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
  NCT07327489 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Frederick
• Project: Every Child for Younger Patients With Cancer
  NCT02402244 · Phase: Not specified · Ages: Up to 25 Years · Sex: All (male and female) · Maryland: Baltimore, Bethesda
• SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
  NCT06743126 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore
• SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
  NCT03452774 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Maryland: Baltimore, Bethesda, Silver Spring, Towson
• Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
  NCT06697301 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Bethesda
• Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
  NCT06585410 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Rockville
• Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
  NCT05379985 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore
• Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
  NCT05727904 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Maryland: Bethesda
• TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
  NCT04485013 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Bethesda, Silver Spring
• Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
  NCT06500455 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore, Bel Air, Columbia, Easton
• The Cancer of the Pancreas Screening-5 CAPS5)Study
  NCT02000089 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore